Joe Banks
Family Medicine · Indianapolis, INNPI 1154508075
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $294,100 of the $294,246 with a category attached, or 100.0%. CSL Plasma Inc. accounts for 79.0% of it on its own, with 5 other manufacturers making up the rest. Among family medicine clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 332 payments — averaging $886.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Plasma Inc.$232K
- CSL Behring$62K
- Neurocrine Biosciences, Inc.$81
- Acadia Pharmaceuticals Inc$27
- Teva Pharmaceuticals USA, Inc.$19
- GSK$19
What the payments were for
- Consulting fees$294,100100%
- Food & beverage$1460%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Plasma Inc. | 269 | $232,391 |
| CSL Behring | 57 | $61,709 |
| Neurocrine Biosciences, Inc. | 3 | $81 |
| Acadia Pharmaceuticals Inc | 1 | $27 |
| Teva Pharmaceuticals USA, Inc. | 1 | $19 |
| GSK | 1 | $19 |
How this compares
$294,246 in reported general payments places this provider in the 95th percentile of 2,709 family medicine providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 105 | $65,351 |
| OzempicSemaglutide | 62 | $63,008 |
| RybelsusSemaglutide | 19 | $27,796 |
| JanuviaSitagliptin Phosphate | 33 | $23,644 |
| MounjaroTirzepatide | 20 | $22,003 |
| JardianceEmpagliflozin | 28 | $18,293 |
| XareltoRivaroxaban | 26 | $16,896 |
| TrulicityDulaglutide | 14 | $15,650 |
| EntrestoSacubitril/Valsartan | 17 | $12,738 |
| Spiriva RespimatTiotropium Bromide | 16 | $10,248 |
| VascepaIcosapent Ethyl | 27 | $9,279 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $7,836 |
| TradjentaLinagliptin | 11 | $6,073 |
| Atorvastatin Calcium | 583 | $5,886 |
| MyrbetriqMirabegron | 12 | $5,795 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $19 | $7,83612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,709 family medicine providers in Indiana.
Other family medicine in Indianapolis
- Richard TannerIndianapolis$1.6M
- Richard FeldmanIndianapolis$476K
- Jakoda SniderIndianapolis$107K
- Robert ClutterIndianapolis$77K
- Blair BrengleIndianapolis$17K
- James AndryBloomington$715K
- Anthony InzerelloEvansville$308K
- Steven GatewoodElwood$281K
- Shekar PushpalaCarmel$239K
- Victoria MoyerKokomo$188K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.